Layline Advisors’s ResMed RMD Stock Holding History

Layline Advisors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$277K	Sell	1,421 -10	-0.7%	-$2.07K	0.25%	54
2026 Q1	$321K	Buy	+1,431	New	+$357K	0.36%	41

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Layline Advisors's RMD Position: Q2 2026 in Review

Layline Advisors reduced its ResMed (RMD) stake by 0.7% in Q2 2026, selling an estimated $2.07K and leaving 1,421 shares worth $277K. The position accounts for 0.25% of the portfolio, ranked #54.

Layline Advisors first reported a position in RMD in Q1 2026 and has held it in 2 quarters since. The position peaked at $321K in Q1 2026. 891 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

Layline Advisors held 1,421 shares of ResMed worth $277K as of Q2 2026.
Layline Advisors sold 10 ResMed shares in Q2 2026, an estimated $2.07K.
ResMed made up 0.25% of Layline Advisors's portfolio in Q2 2026, its #54 holding.
Layline Advisors first reported a position in ResMed in Q1 2026 and has held it in 2 quarters since.
Layline Advisors's ResMed position peaked at $321K in Q1 2026.
891 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Layline Advisors's 13F filing for Q2 2026, filed 20 Aug 2026.